Theravance Biopharma, Inc.
TBPH
$8.44
-$0.33-3.76%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 18.75M | 16.87M | 14.26M | 14.50M | 17.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.75M | 16.87M | 14.26M | 14.50M | 17.57M |
| Cost of Revenue | 9.45M | 9.27M | 9.95M | 8.97M | 8.31M |
| Gross Profit | 9.30M | 7.60M | 4.30M | 5.54M | 9.25M |
| SG&A Expenses | 18.50M | 16.88M | 17.06M | 16.74M | 15.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.95M | 26.14M | 27.01M | 25.71M | 24.16M |
| Operating Income | -9.20M | -9.28M | -12.75M | -11.21M | -6.60M |
| Income Before Tax | -8.94M | -10.05M | -15.22M | -10.40M | -5.02M |
| Income Tax Expenses | 6.59M | 2.65M | 1.31M | 1.26M | 3.49M |
| Earnings from Continuing Operations | -15.53M | -12.70M | -16.53M | -11.66M | -8.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.53M | -12.70M | -16.53M | -11.66M | -8.51M |
| EBIT | -9.20M | -9.28M | -12.75M | -11.21M | -6.60M |
| EBITDA | -8.78M | -8.85M | -11.97M | -11.13M | -6.21M |
| EPS Basic | -0.31 | -0.26 | -0.34 | -0.24 | -0.17 |
| Normalized Basic EPS | -0.11 | -0.11 | -0.16 | -0.13 | -0.07 |
| EPS Diluted | -0.31 | -0.26 | -0.34 | -0.24 | -0.17 |
| Normalized Diluted EPS | -0.11 | -0.11 | -0.16 | -0.13 | -0.07 |
| Average Basic Shares Outstanding | 49.31M | 49.04M | 48.75M | 48.28M | 49.42M |
| Average Diluted Shares Outstanding | 49.31M | 49.04M | 48.75M | 48.28M | 49.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
